Vol. 23/No. 3 | OncologyLive

Folding CAR T-cell Therapy Into Relapsed/Refractory MCL Treatment

March 09, 2022

Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.

Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus

February 10, 2022


A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset.

Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma

February 09, 2022

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

Treatment Strategies for Relapsed/Refractory MCL Represent a Unique Challenge

February 08, 2022

Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 04, 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Serious Concerns Cloud Potential Benefit of Liquid Biopsy in Cancer Screening

February 03, 2022

Maurie Markman, MD, explains the concerns surrounding liquid biopsies in cancer screening, and why regulatory agencies should be cautious and not approve any proposed molecularly based cancer diagnostic screening strategy until the tool is shown to effect cancer-specific survival compared with a control population not undergoing such testing.